You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 281 No. 24, June 23, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Meta-analysis of Tacrine for Alzheimer Disease: The Influence of Industry Sponsors

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The recent favorable meta-analysis of tacrine for treating Alzheimer disease by Dr Qizilbash and colleagues1 did not consider the potential influence of corporate sponsorship on the reported studies. Studies without corporate support found no clinical effect (references 1, 13, 14, 16, and 21 in the article). All but 1 (reference 24) of the manufacturer-supported studies found clinical benefit (references 15, 17-20, and 22). We could not locate 1 study (reference 23).

Corporate support took the form of authors who were employed by the manufacturer, received grants, or held stocks or stock options of the manufacturer; in-house research of methodological or statistical analysis provided by the manufacturer; or unidentified support. Four of the authors of the favorable meta-analysis are listed as having had or currently receiving support from the manufacturer of tacrine or similar agents.

Industry-supported research tends to showcase products.2-3 This does not invalidate such studies, industry . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
, , , , , , and
JAMA. ;280():1777-1782.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Therapy for Alzheimer's disease: how effective are current treatments?
Lanctot et al.
Therapeutic Advances in Neurological Disorders 2009;2:163-180.
ABSTRACT  

Donepezil is more effective than galantamine for mild to moderate Alzheimer's disease
Warner
Evid. Based Ment. Health 2004;7:77-77.
FULL TEXT  

Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin et al.
BMJ 2003;326:1167-1170.
ABSTRACT | FULL TEXT  

First among Equals?: Does drug treatment for dementia claim more than its fair share of resources?
Heller and Heller
Dementia 2003;2:7-19.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.